Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
Werewolf Therapeutics (Nasdaq: HOWL) announced it will present two posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting in Houston, Texas, from November 6-10, 2024. The first poster, titled 'INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models' (Abstract 955), will be presented on November 8. The second poster, 'The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study' (Abstract 672), will be presented on November 9.
Both presentations will take place at the George R. Brown Convention Center - Exhibit Halls A B. Werewolf Therapeutics is a biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for cancer treatment.
Werewolf Therapeutics (Nasdaq: HOWL) ha annunciato che presenterà due poster alla 39ª Riunione Annuale della Società per l'Immunoterapia del Cancro (SITC) a Houston, Texas, dal 6 al 10 novembre 2024. Il primo poster, intitolato 'Le Molecole INDUKINE™ che Consegna Vari Citochine Utilizzano Meccanismi Unici di Azione per Promuovere l'Efficacia Antitumorale nei Modelli Tumorali Sinergici Murini' (Abstract 955), sarà presentato l'8 novembre. Il secondo poster, 'Il pro-farmaco IL-12 attivato dal tumore WTX-330 ha espanso/attivato i linfociti infiltranti tumorali e ha causato regressione tumorale nei pazienti con tumori solidi refrattari: Dati intermedi da uno studio Ph1 in corso' (Abstract 672), sarà presentato il 9 novembre.
Entrambe le presentazioni si svolgeranno al George R. Brown Convention Center - Aule Espositive A B. Werewolf Therapeutics è un'azienda biofarmaceutica focalizzata sullo sviluppo di terapie attivate condizionalmente per stimolare il sistema immunitario per il trattamento del cancro.
Werewolf Therapeutics (Nasdaq: HOWL) anunció que presentará dos posters en la 39ª Reunión Anual de la Sociedad para la Inmunoterapia del Cáncer (SITC) en Houston, Texas, del 6 al 10 de noviembre de 2024. El primer poster, titulado 'Las Moléculas INDUKINE™ Entregando Varios Citoquinas Utilizan Mecanismos Únicos de Acción para Impulsar la Eficacia Antitumoral en Modelos Tumorales Sinérgicos Murinos' (Resumen 955), se presentará el 8 de noviembre. El segundo poster, 'El pro-fármaco IL-12 activado por el tumor WTX-330 expandió/activó los linfocitos infiltrantes tumorales y causó regresión tumoral en pacientes con tumores sólidos refractarios: Datos intermedios de un estudio Ph1 en curso' (Resumen 672), se presentará el 9 de noviembre.
Ambas presentaciones tendrán lugar en el George R. Brown Convention Center - Salones de Exposición A B. Werewolf Therapeutics es una empresa biofarmacéutica centrada en el desarrollo de terapias activadas condicionalmente para estimular el sistema inmunológico para el tratamiento del cáncer.
Werewolf Therapeutics (Nasdaq: HOWL)은 2024년 11월 6일부터 10일까지 텍사스 휴스턴에서 열리는 암 면역요법 학회(SITC) 제39회 연례 회의에서 두 개의 포스터를 발표한다고 발표했습니다. 첫 번째 포스터의 제목은 'INDUKINE™ 분자가 다양한 사이토카인을 전달하며 고유한 작용 메커니즘을 이용해 생쥐 동종 종양 모델에서 항종양 유효성을 유도한다' (초록 955)이며, 11월 8일에 발표됩니다. 두 번째 포스터는 '종양 활성화 IL-12 전구체 WTX-330이 종양 침윤 림프구를 확장/활성화하고 재발성 고형종양 환자에서 종양 퇴행을 유도했다: 진행 중인 1상 연구의 중간 데이터' (초록 672)이며, 11월 9일에 발표됩니다.
두 발표는 조지 R. 브라운 컨벤션 센터 - 전시홀 A B에서 진행됩니다. Werewolf Therapeutics는 면역 체계를 자극하여 암 치료를 위한 조건부 활성화 치료제를 개발하는 생명공학 회사입니다.
Werewolf Therapeutics (Nasdaq: HOWL) a annoncé qu'il présentera deux affiches lors de la 39ème Réunion Annuelle de la Société pour l'Immunothérapie du Cancer (SITC) à Houston, Texas, du 6 au 10 novembre 2024. La première affiche, intitulée 'Les molécules INDUKINE™ délivrant divers cytokines utilisent des mécanismes d'action uniques pour stimuler l'efficacité anti-tumorale dans des modèles tumoraux syngéniques murins' (Résumé 955), sera présentée le 8 novembre. La deuxième affiche, 'Le pro-médicament IL-12 activé par le tumor WTX-330 a élargi/activé les lymphocytes infiltrants tumoraux et a provoqué une régression tumorale chez des patients atteints de tumeurs solides réfractaires : Données intermédiaires d'une étude Ph1 en cours' (Résumé 672), sera présentée le 9 novembre.
Les deux présentations auront lieu au George R. Brown Convention Center - Halls d'Exposition A B. Werewolf Therapeutics est une entreprise biopharmaceutique axée sur le développement de thérapies activées de manière conditionnelle pour stimuler le système immunitaire dans le traitement du cancer.
Werewolf Therapeutics (Nasdaq: HOWL) hat angekündigt, dass es auf dem 39. Jahresmeeting der Society for Immunotherapy of Cancer (SITC) in Houston, Texas, vom 6. bis 10. November 2024, zwei Poster präsentieren wird. Das erste Poster mit dem Titel 'INDUKINE™ Moleküle, die verschiedene Zytokine liefern, nutzen einzigartige Wirkmechanismen, um die Antitumor-Effizienz in murinen syngenetischen Tumormodellen zu steigern' (Abstract 955), wird am 8. November präsentiert. Das zweite Poster, 'Das tumoreaktivierte IL-12-Prodrug WTX-330 hat Tumorinfiltrierende Lymphozyten erweitert/aktiviert und eine Tumorrückbildung bei Patienten mit refraktären soliden Tumoren verursacht: Zwischenbericht aus einer laufenden Phase-1-Studie' (Abstract 672), wird am 9. November präsentiert.
Beide Präsentationen finden im George R. Brown Convention Center - Ausstellungshallen A B statt. Werewolf Therapeutics ist ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung von bedingt aktivierten Therapeutika zur Stimulation des Immunsystems für die Krebsbehandlung konzentriert.
- None.
- None.
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
Details for the poster presentations are as follows:
Title: INDUKINE™ Molecules Delivering Various Cytokines Utilize Unique Mechanisms of Action to Drive Anti-Tumor Efficacy in Murine Syngeneic Tumor Models
Abstract Number: 955
Session Date and Time: Friday, Nov. 8, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B
Title: The tumor-activated IL-12 prodrug WTX-330 expanded/activated tumor infiltrating lymphocytes and caused tumor regression in patients with refractory solid tumors: Interim data from an ongoing Ph1 study
Abstract Number: 672
Session Date and Time: Saturday, Nov. 9, 2024; 9 a.m.–8:30 p.m.
Location: George R. Brown Convention Center - Exhibit Halls A B
About Werewolf Therapeutics
Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. Werewolf leverages its proprietary PREDATOR® platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. The Company’s INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Werewolf’s most advanced clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. Werewolf is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor and WTX-330 as a single agent in multiple tumor types and Non-Hodgkin Lymphoma. To learn more visit www.werewolftx.com.
WEREWOLF®, the WEREWOLF logo, PREDATOR®, INDUKINE™ and other Werewolf trademarks, service marks, graphics and logos are trade names, trademarks or registered trademarks of Werewolf Therapeutics, Inc., in the United States or other countries. All rights reserved.
Investor Contact:
John Norton
Precision AQ
212.362.1200
John.Norton@precisionaq.com
Media Contact:
Amanda Sellers
Deerfield Group
301.332.5574
amanda.sellers@deerfieldgroup.com
Company Contact:
Ellen Lubman
Chief Business Officer
Werewolf Therapeutics
elubman@werewolftx.com
FAQ
What posters will Werewolf Therapeutics (HOWL) present at SITC 2024?
When and where will SITC's 39th Annual Meeting take place?
What is the focus of Werewolf Therapeutics' (HOWL) research?
What are the abstract numbers for Werewolf Therapeutics' (HOWL) SITC 2024 presentations?
